Fr. 215.00

Tamoxifen - Pioneering Medicine in Breast Cancer

English · Hardback

Shipping usually within 2 to 3 weeks (title will be printed to order)

Description

Read more

Tamoxifen is a pioneering medicine for the treatment and prevention of breast cancer. It is the first drug targeted therapy in cancer to be successful. Tamoxifen targets the tumor estrogen receptor. The therapy is known to have saved the lives of millions of women over the past 40 years.
This monograph, written by V. Craig Jordan - known as the "father of tamoxifen" - and his Tamoxifen Team at the Georgetown University Washington DC, illustrates the journey of this milestone in medicine. It includes a personal interview with V. Craig Jordan about his four decades of discovery in breast cancer research and treatment. V. Craig Jordan was there for the birth of tamoxifen as he is credited for reinventing a "failed morning after contraceptive" to become the "gold standard" for the treatment of breast cancer. He contributed to every aspect of tamoxifen application in therapeutics and all aspects of tamoxifen's pharmacology. He discovered the selective estrogen receptor modulators (SERMs) and explored the new biology of estrogen-induced apoptosis.

List of contents

Discovery and Pharmacology of Nonsteroidal Estrogens and Antiestrogens.- Tamoxifen Goes Forward Alone.- Metabolites of Tamoxifen as the Basis of Drug Development.- Adjuvant Therapy - The Breakthrough.- The Wisconsin Story in the 1980's: Discovery of Target Site Specific Estrogen Action.- Carcinogenesis and Tamoxifen.- Chemoprevention: Cinderella waiting for the ball.- Tamoxifen and Raloxifene head to head: The STAR TRIAL.- Acquired resistance to Tamoxifen: back to the beginning.- The legacy of Tamoxifen.- Appendix: Four decades of discovery in breast cancer research and treatment - an interview with V. Craig Jordan by Marc Poirot.- Selected Awards that Recognize the Contribution of Tamoxifen and Raloxifene to Medicine.

Summary

Tamoxifen is a pioneering medicine for the treatment and prevention of breast cancer. It is the first drug targeted therapy in cancer to be successful. Tamoxifen targets the tumor estrogen receptor. The therapy is known to have saved the lives of millions of women over the past 40 years.
This monograph, written by V. Craig Jordan - known as the “father of tamoxifen” - and his Tamoxifen Team at the Georgetown University Washington DC, illustrates the journey of this milestone in medicine. It includes a personal interview with V. Craig Jordan about his four decades of discovery in breast cancer research and treatment. V. Craig Jordan was there for the birth of tamoxifen as he is credited for reinventing a “failed morning after contraceptive” to become the “gold standard” for the treatment of breast cancer. He contributed to every aspect of tamoxifen application in therapeutics and all aspects of tamoxifen’s pharmacology. He discovered the selective estrogen receptor modulators (SERMs) and explored the new biology of estrogen-induced apoptosis.

Additional text

From the book reviews:
“This is a book that had to be written. … This book should be available in every oncology department. The story will interest clinicians and laboratory scientists alike. It has both historical value and value as a guide that will illuminate the path to successful involvement in cancer research for younger cancer researchers.” (R. M. Lowenthal, Inflammopharmacology, Vol. 22 (3), June, 2014)

“This is a very well-written, readable book for anyone who has an interest in the prevention and treatment of breast cancer, ranging from those involved in drug discovery to those who are treating and taking care of patients with breast cancer. Likewise, anyone who has a loved one who has, or is at high risk for, breast cancer will find this an excellent read. … It is a well-done and interesting read.” (Thomas L. Pazdernik, Doody’s Book Reviews, November, 2013)

Report

From the book reviews:
"This is a book that had to be written. ... This book should be available in every oncology department. The story will interest clinicians and laboratory scientists alike. It has both historical value and value as a guide that will illuminate the path to successful involvement in cancer research for younger cancer researchers." (R. M. Lowenthal, Inflammopharmacology, Vol. 22 (3), June, 2014)
"This is a very well-written, readable book for anyone who has an interest in the prevention and treatment of breast cancer, ranging from those involved in drug discovery to those who are treating and taking care of patients with breast cancer. Likewise, anyone who has a loved one who has, or is at high risk for, breast cancer will find this an excellent read. ... It is a well-done and interesting read." (Thomas L. Pazdernik, Doody's Book Reviews, November, 2013)

Product details

Authors V C Jordan, V. Craig Jordan, Philipp Maximov, Philipp Y Maximov, Philipp Y. Maximov, Russell McDaniel, Russell E McDaniel, Russell E. McDaniel
Publisher Springer, Basel
 
Languages English
Product format Hardback
Released 11.04.2013
 
EAN 9783034806633
ISBN 978-3-0-3480663-3
No. of pages 199
Dimensions 163 mm x 242 mm x 17 mm
Weight 474 g
Illustrations XXII, 199 p. 54 illus.
Series Milestones in Drug Therapy
Milestones in Drug Therapy
Subject Natural sciences, medicine, IT, technology > Medicine > Non-clinical medicine

Customer reviews

No reviews have been written for this item yet. Write the first review and be helpful to other users when they decide on a purchase.

Write a review

Thumbs up or thumbs down? Write your own review.

For messages to CeDe.ch please use the contact form.

The input fields marked * are obligatory

By submitting this form you agree to our data privacy statement.